Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Ureteral Neoplasms 2Carcinoma, Transitional Cell 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Carcinoma 1

Interventions

pembrolizumab 91Gemcitabine 55Nivolumab 49Cisplatin 38atezolizumab 31Carboplatin 30avelumab 25enfortumab vedotin 23Docetaxel 23Magnetic Resonance Spectroscopy 18Ipilimumab 17Paclitaxel 16Mitomycin 15Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Transitional Cell × Nephroureterectomy × Clear all
NCT06262516 2025-09-05

Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

Case Comprehensive Cancer Center

Phase NA Recruiting
94 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT00751140 2017-05-30

Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
20 enrolled 7 charts
Genitourinary

Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡